Semaglutide Use Linked to Lower Bone Fracture Risk in Patients with Type 2 Diabetes Compared to Other Anti-Obesity Medications
In a landmark presentation at the ENDO 2026 annual meeting, researchers unveiled findings that suggest semaglutide, a prominent glucagon-like peptide-1…
